Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia
出版年份 2017 全文链接
标题
Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia
作者
关键词
-
出版物
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 98, Issue 4, Pages 363-370
出版商
Wiley
发表日期
2016-12-10
DOI
10.1111/ejh.12836
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse
- (2015) M Hahn et al. BONE MARROW TRANSPLANTATION
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
- (2013) Simon E. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
- (2013) A C Logan et al. LEUKEMIA
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
- (2012) Sebastian Böttcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies
- (2011) Sebastian Böttcher et al. BLOOD REVIEWS
- Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
- (2010) P. Dreger et al. BLOOD
- State of the art treatment of chronic lymphocytic leukaemia
- (2010) Michael Hallek et al. BLOOD REVIEWS
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Defining the Intensity of Conditioning Regimens: Working Definitions
- (2009) Andrea Bacigalupo et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation
- (2009) L. Farina et al. HAEMATOLOGICA
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
- (2008) L. Z. Rassenti et al. BLOOD
- Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
- (2008) C. S. Tam et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication
- (2008) F. Bosch et al. CLINICAL CANCER RESEARCH
- Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis
- (2008) Johannes Schetelig et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
- (2008) Mohamed L. Sorror et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now